In this podcast episode, Bruce Bassi talks with Payton Nyquvest, the founder and CEO of Numinus, about the future of mental health care and the role of psychedelic-assisted therapy. The conversation delves into historical shifts in acceptance of psychedelics, the importance of safety and regulatory protocols, and the need for comprehensive training for clinicians. Payton highlights the promise of psychedelics for curative intent and discusses the potential FDA approval of MDMA and psilocybin. The discussion also touches on the importance of mental wellness and preventative mental health care.Host: Bruce Bassi MDMore resources, including a full transcript, can be found at our podcast website: https://www.telepsychhealth.com/futurepsychiatrypodcast/We are always looking to grow and learn more about the field of tech and mental health. If you have an idea for the show, want to suggest a guest, or have a suggestion, please feel to message us through our website's contact page. If you want to support the show, please like on Facebook, and follow us on Instagram, and Tiktok and subscribe on Youtube.As always, the content is for educational purposes and is not medical advice. If you are having a medical or psychiatric emergency please contact 911.

Ver todos los episodios